RE: Re: This is money2 May 2023 09:40
Encouragingly, as the launch of Eroxon builds in Europe, Futura expects to generate maiden commercial revenues this year.
“Given the lack of visibility with regards to either timing or quantum of these revenues, we haven’t yet factored them into our forecasts, but these, together with other potential sources of income mean that we are very comfortable that Futura is well funded to deliver without needing to turn to equity markets,” said Liberum in a note to clients.
“We leave our forecasts largely unchanged. The shares continue to trade at a discount to our estimate of fair value, and we see the FDA decision on US market authorisation in Q2 as an important catalyst to closing this.”